International Regulatory Resource Manual
This article was originally published in The Rose Sheet
Executive SummaryCosmetic Toiletry and Fragrance Association publishes the sixth edition of its guide to the regulatory environment of major world markets, trade organization announces May 18. The manual has been updated to include the cosmetic regulations and requirements of 74 countries, providing information on ingredient restrictions, labeling, product registration requirements and contacts for government agencies, professional groups and trade associations in each country. The manual also contains citations and analysis of laws that govern cosmetic products, as well as information on products that can be regulated differently from one country to the next, such as sunscreens. The manual is available for $375 for CTFA members and $575 for non-members; it can be purchased from the CTFA Web site...
You may also be interested in...
REACH and Dr. Fresh, as well as Firefly kids’ toothbrushes and mouth rinses featuring popular comic book and cartoon characters, will join Perrigo’s Ranir division under the $113m cash deal, which is subject to federal bankruptcy court approval but expected to close in the 2020 first quarter.
Subject to the approval of a federal bankruptcy court presiding over High Ridge Brands’ Chapter 11 case, private equity firm Tengram will add a raft of personal cleansing and hair-care brands to its portfolio while bringing back former High Ridge CEO James Daniels to head up the collection’s rejuvenation.
US FDA commissioner Stephen Hahn and ORA associate commissioner for regulatory affairs Judith McMeekin said in a joint 24 February statement that the agency continues to aggressively monitor the market for any firms selling products with fraudulent COVID-19 prevention and treatment claims. The officials also explained that the FDA has the authority under FDASIA to ask for records from drug manufacturers in lieu of conducting facility inspections. It can't do the same for device companies, however, because no similar provision exists. The FDA had announced on 14 February that it paused all inspections of Chinese manufacturing facilities in the near-term.